CSIMarket Company Name, Ticker, Competitors, else..
 
Revolution Medicines Inc   (RVMD)
Other Ticker:  
 
 
Price: $50.4800 $0.98 1.980%
Day's High: $51 Week Perf: 6.63 %
Day's Low: $ 49.19 30 Day Perf: 20.28 %
Volume (M): 1,299 52 Wk High: $ 51.00
Volume (M$): $ 65,589 52 Wk Avg: $34.58
Open: $49.43 52 Wk Low: $15.44



 Market Capitalization (Millions $) 5,514
 Shares Outstanding (Millions) 109
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -331
 Cash Flow (TTM) (Millions $) 180
 Capital Exp. (TTM) (Millions $) 8

Revolution Medicines Inc
Revolution Medicines Inc is a biopharmaceutical company that specializes in the discovery and development of new medicines targeting frontier oncology and inflammatory diseases. The company utilizes a proprietary integrated technology platform to identify novel molecules and develop therapies that could potentially transform patients' lives.

Revolution Medicines focuses on targeting elusive and challenging signaling pathways within cancer cells through precision medicines. By identifying and inhibiting these unique oncogenic targets, the company aims to disrupt the progression of cancer and improve patient outcomes.

The company's approach involves a deep understanding of the underlying biology of diseases and the development of small molecule inhibitors that can selectively interrupt disease-causing pathways. Revolution Medicines' research and development efforts are guided by a combination of molecular understanding, computational biology, and medicinal chemistry expertise.

With a goal of developing breakthrough medicines, Revolution Medicines collaborates with academic institutions, biotech partners, and pharmaceutical companies to advance its drug candidates into clinical trials. The company has a pipeline of various targeted therapies in different stages of development, with a focus on treating cancers that have limited treatment options.

In summary, Revolution Medicines Inc is a biopharmaceutical company that aims to revolutionize the treatment of cancer and inflammatory diseases by developing precision medicines that target specific disease-causing pathways. Through its innovative approaches and collaborations, the company seeks to provide better therapeutic options to patients in need.


   Company Address: 700 Saginaw Drive Redwood City 94063 CA
   Company Phone Number: 481-6801   Stock Exchange / Ticker: NASDAQ RVMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Revolution Medicines Unveils RMC-6236: Transforming Cancer Treatment with a Breakthrough RAS(ON) Inhibitor.

Published Tue, Apr 9 2024 7:35 PM UTC

Revolution Medicines, a leading biotechnology company at the forefront of cancer research, has recently announced a groundbreaking discovery in the field of oncology. The company's publication and presentation on their investigational RAS(ON) multi-selective tri-complex inhibitor, RMC-6236, at the AACR 2024 Conference in San Diego has garnered significant attention. This dev...
Clinical Study

Revolution Medicines Unveils Groundbreaking RAS Inhibitor with Unprecedented Anti-Tumor Activity in Pancreatic Cancer Models

Published Mon, Apr 8 2024 3:37 PM UTC

Revolution Medicines Announces Groundbreaking Discovery and Preclinical Profile of New Class of RAS(ON) Multi-Selective Inhibitors with Unprecedented Anti-Tumor Activity in RAS-Mutant Pancreatic Cancer ModelsRevolution Medicines, a leading biotechnology company focused on developing innovative cancer treatments, has recently made significant progress in the field of oncology...
Revolution Medicines Inc

Revolution Medicines Inc Reports Increased Deficit in Recent Fiscal Period; Promising Clinical Data Ignites Hope for Future Performance

Revolution Medicines Inc Reports Increased Deficit in Recent Fiscal Period, But Encouraging Clinical Data Fuels Optimism for Future Performance
Investors of Revolution Medicines Inc expressed concerns as the biotechnology company reported an increased deficit for the most recent fiscal period. However, promising clinical data for their leading RAS(ON) Inhibitors has sparked optimism for the company's future performance.
For the most recent fiscal period, Revolution Medicines Inc saw their deficit per share rise to $-0.99, compared to $-0.87 in the previous year. Additionally, their deficit increased from $-0.92 per share from the previous quarter. Despite these figures, the company's revenue remained stagnant, sitting at $0.00 million, the same as the corresponding quarter a year prior, and slightly lower than the previous quarter's $3.82 million.
Revolution Medicines Inc

Revolution Medicines Inc Faces Mounting Difficulties as Revenue Plummets and Stock Improvement Masks Financial Struggles



Revolution Medicines Inc, a pharmaceutical company trading on the NASDAQ, has experienced a notable stock improvement of 6.47% over the past month and 23.23% in the last 12 months. However, recent financial results paint a different picture, indicating a challenging fiscal quarter closing on June 30, 2023. With revenue plummeting by 58.052% to $3.82 million and a widened shortfall of $-0.92 per share, the company is facing mounting difficulties. This shortfall is an increase from the same quarter the previous year, as well as from the prior quarter. Additionally, Revolution Medicines Inc witnessed a decline in accounts receivable, which some analysts attribute to slowing demand. It is crucial to examine how these facts might impact the company's future.
1. Declining Revenue:
The most concerning aspect of Revolution Medicines Inc's financial results is the sharp decline in revenue. With a significant 58.052% decrease to $3.82 million, the company's ability to generate income has been severely affected. This decrease has occurred sequentially, falling by 45.48% from the previous quarter's revenue of $7.01 million. Such a substantial drop hints at potential issues within the company's product offerings or competitive dynamics.
Revolution Medicines Inc

Revolution Medicines Inc Struggles with Steep Decline in Revenue, Poses Worries for Investors

Investors in Revolution Medicines Inc (RVMD) may be feeling concerned about the company's future prospects after it reported a significant loss in its fiscal first quarter of 2023. The lower turnover has resulted in fading revenues, and the increased deficit has left the company in a difficult position.
In the fiscal first quarter of 2023, RVMD recorded a net loss of $-0.72 per share, compared to the prior period when the company recorded a net loss of $-0.56 per share. The revenue for the same period also declined by -7.443%, falling from $15.33 million to $7.01 million year-on-year. The decline in revenue was primarily due to reduced turnover, which is a worrying sign for the company.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com